Here’s Why Analysts are Bullish on Soleno Therapeutics (SLNO)

Company Overview - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is recognized as one of the best stocks to buy for the next three months according to hedge funds [1] - The company specializes in developing and commercializing novel treatments for rare diseases [3] Recent Developments - The company announced the commercial launch of VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome [2] - Since the approval, Soleno has received 646 patient start forms from 295 unique prescribers, covering over 100 million insured lives in the US [2] - Soleno is also pursuing marketing approval for VYKAT XR in the European Union through the European Medicines Agency [2] - The company has presented clinical data at major medical conferences to enhance awareness regarding the drug's safety and efficacy [2] Analyst Ratings - Analysts have shown a bullish outlook on the stock, with TD Cowen analyst Tyler Van Buren maintaining a Buy rating and a price target of $120 [3] - Oppenheimer's Leland Gershell also reiterated a Buy rating with a price target of $110 [3]